Effects of the COVID-19 Pandemic on Patients Living with Vasculitis Shubhasree Banerjee, MD, MBBS – University of Pennsylvania
9:00 AM – 11:00 AM ET
Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study Sara Thietart – Cochin Hospital
9:00 AM – 11:00 AM ET
Clinical Presentations and Follow-up Results of Granulomatosis with Polyangiitis: An Analysis of 8 Years Clinical Experience with 220 Patients from a National Referral Center Samira Alesaeidi, MD – Tehran university of medical sciences
9:00 AM – 11:00 AM ET
WITHDRAWN
9:00 AM – 11:00 AM ET
Characterization of ANCA-Associated Vasculitis Among African American Patients Sehris Khawaja, DO – Capital Health
9:00 AM – 11:00 AM ET
Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans Luis Palomino, MD – University of Alabama Hospital
9:00 AM – 11:00 AM ET
Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data Zachary Wallace, MD, MSc – Massachusetts General Hospital
9:00 AM – 11:00 AM ET
Declining In-Hospital Mortality in Vasculitis: A 17-year U.S. National Study Jasvinder Singh, MD, MPH – University of Alabama at Birmingham
9:00 AM – 11:00 AM ET
Outcomes of Hospitalizations for Acute Myocardial Infarction in Patients with ANCA Associated Vasculitis from the National Inpatient Sample Atefeh Vafa, MD – USF
9:00 AM – 11:00 AM ET
Reduced Risk of Cardiovascular Diseases Events with Renal Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System Zachary Wallace, MD, MSc – Massachusetts General Hospital
9:00 AM – 11:00 AM ET
Prevalence of ANCA-associated Vasculitis and Spatial Association with Quarries in a French Northeast Region: A Capture-recapture and Geospatial Analysis Stéphane Giorgiutti, -None- – Department of Clinical Immunology and Internal Medicine, Hôpitaux Universitaires de Strasbourg
9:00 AM – 11:00 AM ET
Anti-IL5 Therapy for Eosinophilic Granulomatosis with Polyangiitis (EGPA) - An 18 Month Follow-up Study as a Steroid Sparing Therapeutic Approach Allyson Egan, MD – Vasculitis & Lupus Centre, Cambridge University Hospital
9:00 AM – 11:00 AM ET
The Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis Matthew Koster, MD – Mayo Clinic
9:00 AM – 11:00 AM ET
An Evaluation of Real World Use of Biologics in Rare Systemic Vasculitides During Routine Clinical Care in the US Kathryn Starzyk, MSc – OM1, Inc
9:00 AM – 11:00 AM ET
The Role of Lung Biopsy in Pediatric ANCA-associated Vasculitis Edouard Sayad, MD – Lebanese American University
9:00 AM – 11:00 AM ET
Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study Alojzija Hocevar, MD – University Medical Center Ljubljana
9:00 AM – 11:00 AM ET
Thyroid Disease in Patients with ANCA-Associated Vasculitis Tanaz Kermani, MD – University of California Los Angeles
9:00 AM – 11:00 AM ET
Thyroid Disease in ANCA-associated Vasculitis. a Population-based Study Anna Wilding, MD – Lund University
9:00 AM – 11:00 AM ET
The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres Karl Gisslander, MSc – Lund University/Department of Rheumatology, Skåne University Hospital
9:00 AM – 11:00 AM ET
Prognostic Factors for Mononeuritis Multiplex Associated with ANCA-associated Vasculitis Yutaro Hayashi, MD – Tokyo medical center
9:00 AM – 11:00 AM ET
Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis - A Population-based Study Dennis Tabakovic, MS – Lund University
9:00 AM – 11:00 AM ET
Measuring Disease Activity and Functional Status in Patients with Granulomatosis with Polyangiitis (Wegener's) (GPA) Kinanah Yaseen, MD – cleveland clinic
9:00 AM – 11:00 AM ET
Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV) Jason Springer, MD, MS – Vanderbilt University Medical Center
9:00 AM – 11:00 AM ET
Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis Alvise Berti, MD – University of Trento
9:00 AM – 11:00 AM ET
The Myeloperoxidase (MPO) Anti-Neutrophilic Cytoplasmic Antibody (ANCA) Binding Epitope, MPO447-459 Induces CD4 T-cell Proliferation in Patients with MPO-ANCA-associated Vasculitis Matthew Terrill, MBBS, FRACP – UQ Diamintina Institute
